Langerhans Cell Histiocytosis News and Research

RSS

Origins of the serious cancer-like disease LCH discovered

The origins of the serious cancer-like disease LCH have been identified by researchers from Karolinska Institutet in collaboration with Karolinska University Hospital. The findings presented in Science Immunology may lead to new, targeted treatments.

16 Dec 2022

Cognitive outcomes in survivors of childhood cancers have been largely understudied

In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income.

23 Apr 2021

Fossilized dinosaur tail is home to a 60-million-year-old tumor

The fossilized tail of a young dinosaur that lived on a prairie in southern Alberta, Canada, is home to the remains of a 60-million-year-old tumor.

11 Feb 2020

An unexpected developmental hierarchy in a rare disease affecting young children

Langerhans cell histiocytosis is a rare disease affecting primarily young children. While LCH may heal by itself without treatment in some patients, others require intensive chemotherapy and suffer from long-term consequences, or may even succumb to the disease.

26 Jul 2019

The Swedish Childhood Cancer Foundation awards grant to KI researchers

Ten researchers at Karolinska Institutet have been awarded grants in the Swedish Childhood Cancer Foundation's latest call for funding, during which approximately SEK 62 million was allocated.

19 Apr 2018

Doctors use targeted molecular drugs to treat fatal cancerous blood syndromes

Genomic testing of biopsies from patients with deadly, treatment-resistant cancerous blood syndromes called histiocytoses allowed doctors to identify genes fueling the ailments and use targeted molecular drugs to successfully treat them.

16 Feb 2017

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.

1 Jun 2015

New hope for children with multi-system LCH

A new international study finds that prolonged, intense initial treatment in children with multi-system Langerhans cell histiocytosis can achieve survival rates as high as 84 percent-a full 15 percent improvement over the previous clinical trial in this series.

30 May 2013

Clinical trial shows reduction in mortality for children with severe Langerhans cell histiocytosis

A new international study finds that introducing an increased intensity of chemotherapy in children with severe Langerhans cell histiocytosis (LCH) can reduce the mortality rate for this disorder by as much as 20 percent when the patient demonstrates a rapid response to such treatment.

3 Mar 2008